(Q27860949)

English

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

scientific article (publication date: 22 September 2001)

In more languages

Statements

scholarly article

0 references

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial (English)

0 references

0 references

0 references

0 references

peginterferon alfa-2a

0 references

chronic hepatitis C

1 reference

based on heuristic

inferred from title

peginterferon alfa-2b

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

1

object named as

Michael P Manns

0 references

author name string

M P Manns

1

0 references

J G McHutchison

2

0 references

S C Gordon

3

0 references

V K Rustgi

4

0 references

M Shiffman

5

0 references

R Reindollar

6

0 references

Z D Goodman

7

0 references

K Koury

8

0 references

M Ling

9

0 references

J K Albrecht

10

0 references

John G McHutchison

2

0 references

Stuart C Gordon

3

0 references

Vinod K Rustgi

4

0 references

Mitchell Shiffman

5

0 references

Robert Reindollar

6

0 references

Zachary D Goodman

7

0 references

Kenneth Koury

8

0 references

Mei-Hsiu Ling

9

0 references

Janice K Albrecht

10

0 references

language of work or name

0 references

publication date

22 September 2001

0 references

September 2001

0 references

1 reference

358

0 references

958-65

0 references

958-965

0 references

9286

0 references

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Histopathology of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906102-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(01)06102-5

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27860949&oldid=2112599521"